Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.
MeSH terms
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / therapeutic use
-
Area Under Curve
-
CCR5 Receptor Antagonists*
-
Clinical Trials, Phase II as Topic*
-
Cyclohexanes / antagonists & inhibitors
-
Cyclohexanes / therapeutic use
-
Dose-Response Relationship, Drug
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / drug effects*
-
Humans
-
Maraviroc
-
RNA, Viral / blood
-
Randomized Controlled Trials as Topic*
-
Time Factors
-
Treatment Outcome
-
Triazoles / antagonists & inhibitors
-
Triazoles / therapeutic use
-
Viral Load / statistics & numerical data
Substances
-
Anti-HIV Agents
-
CCR5 Receptor Antagonists
-
Cyclohexanes
-
RNA, Viral
-
Triazoles
-
Maraviroc